Featuring an interview with Dr Adam Brufsky, including the following topics: Trastuzumab deruxtecan (T-DXd) for HER2-low breast cancer; recently presented findings from the DESTINY-BREAST04 trial (0:00) Impact of heterogeneous disease on the detection of HER2-low expression in patients with breast cancer (7:48) Case: A woman with low-volume, asymptomatic and nonvisceral ER-positive, HER2-low breast cancer (13:16) Case: A woman with high-volume, symptomatic and visceral HER2-low breast cancer; treating ER-negative, HER2-low disease (18:44) Toxicities associated with T-DXd (25:25) Ongoing trials evaluating T-DXd in earlier lines of therapy (31:28) CME information and select publications

Ver todos los episodios